Vivani Medical completed enrollment in its LIBERATE-1 trial, testing a six-month GLP-1 implant for weight management.

They were either given weekly exenatide injections or a placebo jab. At the end of the 96-week study those taking exenatide, sold under the brand Bydureon in the UK, saw no benefits compared to ...

Our study demonstrates reduction in postprandial glucose after exenatide injection in adolescents with type 1 diabetes. These effects were associated with delayed gastric emptying, and the results ...

n=8), weekly exenatide injections (Bydureon BCise®, n=8), or weekly 1 mg semaglutide injections (Wegovy®, n=8) for a 9-week treatment duration. Changes in weight will be measured. The study is ...

AstraZeneca announced that the EC green-lighted the new formulation of the once-weekly type-2 diabetes injection, which will be marketed as Bydureon BCise (exenatide 2mg prolonged-release suspension).

Findings showed MDS-UPDRS OFF medication scores had worsened (increased) by 5.7 points in exenatide-treated patients compared with a 4.5 point increase with placebo. Treatment with once-weekly ...

α-Glucosidase inhibitors 0.5 0.8 Weight neutral Frequent GI side effects, three times/day dosing, expensive Exenatide 0.5 1.0 Weight loss Injections, frequent GI side effects, expensive ...

AstraZeneca Plc's (NASDAQ:AZN) Bydureon BCise (exenatide 2 mg prolonged-release suspension for injection) is indicated for type-2 diabetes. Novo Nordisk A/S' (NYSE:NVO) semaglutide is approved as ...

today announced the successful administration of its first GLP-1 (exenatide) implant in the LIBERATE-1™ clinical trial. This milestone marks a critical step toward addressing one of healthcare ...